

FSGS – CT STUDY
Publications and Presentations

February 19, 2013

Peer Reviewed Publications (Reverse Chronological Order)

- Ronald J. Hogg, Aaron Friedman, Tom Greene, Milena Radeva Milos Budisavljevic, Jennifer Gassman, Debbie S Gipson, J. Ashley Jefferson, Eunice G. John, Frederick J Kaskel, Asha Moudgil, Marva Moxey-Mims, Luis A. Ortiz, Jeffrey R. Schelling, William Schnaper, Tarak Srivastava, Howard Trachtman, V. Matti Vehaskari, Craig Wong, Robert P. Woronieki, Scott K. Van Why, Anna Zolotnitskaya. Renal Function and Proteinuria after Successful Immunosuppressive Therapies in Patients with FSGS. A post-hoc analysis of the FSGS Clinical Trial. *Clin J Am Soc Nephrol* 08330812. November, 2012. CJASN 8:211-218, 2013.
- Maria Ferris, Victoria Norwood, Milena Radeva, Jennifer Gassman, Amira Al-Uzri, David Askenazi, Tej Matoo, Maury Pinsk, Amita Sharma, William Smoyer, Jenna Stult, Shefali Vyas, Robert Weiss, Debbie Gipson, Frederick Kaskel, Aaron Friedman, Marva Moxey-Mims, Howard Trachtman. Patient recruitment into a multicenter randomized clinical trial for kidney disease: report of the focal segmental glomerulosclerosis clinical trial (fsgs ct). *Clinical and Translational Science*, February 2013, Volume 6, Issue 1, pages 13–20.
- Vivette D. D’Agati, Joan M. Alster, J. Charles Jennette, David B. Thomas, James Pullman, Daniel A. Savino, Arthur H. Cohen, Debbie S. Gipson, Jennifer J. Gassman, Milena K. Radeva, Marva M. Moxey-Mims, Aaron L. Friedman, Frederick J. Kaskel, Howard Trachtman, Charles E. Alpers, Agnes B. Fogo, Tom Greene, Cynthia C. Nast. Renal Biopsies from the FSGS Clinical Trial Validate the Importance of Histologic Variants *Clin J Am Soc Nephrol*. December 2012, doi: 10.2215/CJN.06100612.
- Changli Wei, Howard Trachtman, Jing Li, Chuanhui Dong, Aaron L. Friedman, Jennifer J. Gassman, June L. McMahan, Milena Radeva, Karsten M. Heil, Agnes Trautmann, Ali Anarat, Sevinc Emre, Gian M. Ghiggeri, Fatih Ozaltin, Dieter Haffner, Debbie S. Gipson, Frederick Kaskel, Dagmar-C. Fischer, Franz Schaefer, Jochen Reiser; the PodoNet and FSGS CT Study Consortia. Characteristics of circulating suPAR in two distinct primary FSGS Cohorts. *JASN*, November 30, 2012 vol.23 no.12 2051-2059.
- Debbie S. Gipson, Howard Trachtman, Frederick J. Kaskel, Tom H. Greene, Milena K. Radeva, Jennifer J. Gassman, Marva M. Moxey-Mims, Ronald J. Hogg, Sandra L. Watkins, Richard N. Fine, Susan L. Hogan, John P. Middleton, V. Matti Vehaskari, Patti A. Flynn, Leslie M. Powell, Suzanne Vento, June L. McMahan, Norman Siegel, Vivette D. D’Agati and Aaron L. Friedman. Clinical trial of Focal Segmental Glomerulosclerosis in children and young adults. *Kidney International*. October 2011; 80(8):868-78.

- Debbie Gipson, Howard Trachtman, Frederick Kaskel, Milena Radeva, Jennifer Gassman, Tom Greene, Marva Moxey-Mims, Ronald Hogg, Sandra Watkins, Richard Fine, John P. Middleton, V. Matti Vehaskari, Susan L Hogan, Suzane Vento, Patti Flynn, Leslie Powell, June McMahan, Norman Siegel, Aaron Friedman. Clinical Trials Treating Focal Segmental Glomerulosclerosis Should Measure Patient Quality of Life. *Kidney International*. 79(6):678-85, 2011 March.
- Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase I Trial of Adalimumab in FSGS: II. Report of the FONT Study Group. *Am J Kidney Dis*. 2010 Jan; 55(1):50-60
- Peysner A, Machardy N, Tarapore F, Machardy J, Powell L, Gipson DS, Savin V, Pan C, Kump T, Vento S, Trachtman H. Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. *BMC Nephrol*. 2010; 11:2
- Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Rosiglitazone and N-Desmethylrosiglitazone Pharmacokinetics Are Altered in Patients with Focal Segmental Glomerulosclerosis (FSGS): I. Report of the Novel Therapies for Resistant FSGS (FONT) Study Group. *Clin J Am Soc Nephrol*. 2009 Jan; 4(1):39-47
- Trachtman H. Educational feature on Focal Segmental Glomerulosclerosis (FSGS): An introduction. *Pediatric Nephrology*. January 2007; 26-27
- Hogg RJ, Middleton J, Vehaskari VM. Focal Segmental Glomerulosclerosis -- Epidemiology Aspects in Children and Adults. *Pediatric Nephrology* 2007; 22:183-186
- Reidy K, Kaskel FJ. Pathophysiology of on Focal Segmental Glomerulosclerosis. *Pediatric Nephrology* 2007; 22:350-354
- Fine R. Recurrence of Nephrotic Syndrome/Focal Segmental Glomerulosclerosis Following Renal Transplantation in Children. *Pediatric Nephrology* 2007; 22:496-502
- Woroniecki RP, Kopp JB. Genetics of Focal Segmental Glomerulosclerosis. *Pediatric Nephrology* 2007; 22:638-644
- Gipson DS, Gibson K, Gipson PE, Watkins S, Moxey-Mims M. Therapeutic Approach to FSGS in Children. CME article. *Pediatric Nephrology* 2007 Jan;22(1):28-36.
- Gipson D and Trachtman H. The Clinical Trial Imperative. Peer reviewed editorial. *Pediatric Nephrology* 2005 Jan; 20(1):5-9

Posters and other Presentations (Alphabetical by first author)

- P Devarajan, M Bennett, M Radeva, D Gipson, F Kaskel, A Friedman, M Moxey-Mims, S Vento, H Trachtman. Neutrophil Gelatinase-Associated Lipocalcin (NGAL) and Alternate Pathway of Complement (APC) Factors as Biomarkers of Response to Treatment in Patients with Focal Segmental Glomerulosclerosis (FSGS)” Neutrophil Gelatinase-Associated Lipocalcin (NGAL) in Focal Segmental Glomerulosclerosis (FSGS): Relationship to Proteinuria. *Pediatric Academic Societies*, January 2010.
- J Gassman, R Fine, A Friedman, D Gipson, T Greene, S Hogan, R Hogg, F Kaskel, J Middleton, M Moxey-Mims, M Radeva, N Siegel* (deceased) , H Trachtman, V M Vehaskari, S Watkins. Multicenter Randomized Clinical Trail of FSGS in Children and Young Adults. *ASN*, November 2009.
- Gassman J, Fine R, Gipson D, Greene T, Hogg R, Kaskel F, McMahan J, Moxey-Mims M, Radeva M, Siegel N*, Trachtman H, Watkins S. A Preliminary Report of the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT). *ASN Renal Week* 2008.
- Gassman J, Trachtman H, Gipson D, Friedman A, Greene T, Vento S, Thompson A, Powell L. Implementing a Second Randomized Trial Enrolling Mid-Study Treatment Failures From the Focal Segmental Glomerularsclerosis (FSGS) Clinical Trial. *Society for Clinical Trials*, 2007.
- DS Gipson, M Radeva, R Fine, A Friedman, J Gassman, T Greene, R Hogg, F Kaskel, M Moxey-Mims, N Siegel*, H Trachtman and S Watkins. Focal Segmental Glomerulosclerosis Clinical Trial. *American Society of Nephrology*, November 2009.
- Greene T, Gassman J, Gipson D, Hogg R, Kaskel F, Moxey-Mims M, Fine R, Trachtman H, Watkins S, Siegel N. Multicenter randomized clinical trial of FSGS in children and young adults. *American Society of Nephrology Renal Week*, Philadelphia, PA, November 8-13, 2005.
- Hogan SL, Gipson DS, Ferris M, Jennette CE, Hu Y, Nachman PH, Jennette JC, Falk RJ. The Life Course of Body Weight and Development of Focal Segmental Glomerulosclerosis. *J Am Soc Nephrol*, Philadelphia, PA 2008.
- Joy MS. Gipson DS. Powell L. MacHardy J. Jennette JC. Vento S. Pan C. Savin V. Eddy A. Fogo AB. Kopp JB. Cattran D. Trachtman H. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. *American Journal of Kidney Diseases*. 55(1):50-60, 2010 Jan. [Clinical Trial, Phase I. Comparative Study. Journal Article. Randomized Controlled Trial. Research Support, N.I.H., Extramural. Research Support, N.I.H., Intramural] UI: 19932542

- Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. *Clinical Journal of The American Society of Nephrology*: 4(1):39-47, 2009 Jan. [Clinical Trial, Phase I. Journal Article. Multicenter Study. Research Support, N.I.H., Extramural. Research Support, N.I.H., Intramural] UI: 19073787
- JP Middleton, P Yorgin, D Gipson, M Radeva, R Fine, A Friedman, J Gassman, T Greene, R Hogg, FJ Kaskel, M Moxey-Mims, N Siegel, H Trachtman, and S Watkins. Prevalence of Blood Pressure Control in the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT) Cohort. *American Society of Nephrology*, November 2009.
- Joy M, Vento S, Gipson D, Trachtman H, et al. Pharmacokinetics of Adalimumab in resistant FSGS: Report of the FONT Network. *American Society of Nephrology*, Philadelphia, PA, November 2008
- Joy M, Gipson D, Dike M, Powell L, Thompson A, Vento S, Trachtman H. Rosiglitazone Pharmacokinetics in Patients with Focal Segmental Glomerulosclerosis: Report of the FONT Study. *JASN Annual Meeting*, San Francisco Nov 2007.
- Li Rong, Zanini S, FSGS-CT Steering Committee, Guay-Woodford L: Comprehensive NPHS2 Mutational Analysis in FSGS-CT Patients and Population Controls. *ASN Renal Week* 2008.
- Middleton J, Thomas D, Kaskel F and The Focal Segmental Glomerulosclerosis Clinical Trial Steering Committee: Appel G, Fine R, Friedman A, Gassman J, Greene T, Gipson D, Hogg R, Moxey-Mims M, Trachtman H, Watkins S, Siegel N. Focal Segmental Glomerulosclerosis: The Need for Improved Treatment Options and the Basis for the Ongoing NIH Clinical Trial. Rounds of The Nephrology Division of Brigham and Women's Hospital, Boston, Massachusetts, April 2007
- Peysner A, Machardy N, Tarapore F, Machardy J, Powell L, Gipson DS, Savin V, Pan C, Kump T, Vento S, Trachtman H. Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. *BMC Nephrology*. 11:2, 2010. [Clinical Trial, Phase I. Journal Article. Research Support, N.I.H., Extramural] UI: 20113498
- M Radeva, H Trachtman, R Fine, A Friedman, J Gassman, D Gipson, T Greene, R Hogg, FJ Kaskel, M Moxey-Mims, S Watkins. Measuring Quality of Life (QOL) in Children and Young Adults in the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT). *Society for Clinical Trials* 2010.
- Radeva M, McMahan J, Gassman J: Optimizing Logistics Under a Three Level Administration System: Coordination of the Focal Segmental Glomerulosclerosis (FSGS) Trial Society for Clinical Trials, 2007

- P Saisawat, G Chernin, V Vega-Warner, B Ovunc, H Saskia, F Hildebrandt, and FSGS-CT Steering Committee. PLCE1 Mutation Analysis in 86 Patients of the NIH FSGS Clinical Trial (FSGS-CT). *ASN* November 2009.
- Thompson A, Dike M, Vento S, Trachtman H, Gipson DS, Greene T, Gassman J, Friedman A, Seigel N. Mechanics of Progress with Novel Therapies for Resistant Focal Segmental Glomerulosclerosis. *Pediatric Academic Societies Meeting*, 2007
- Howard Trachtman, P Devarajan, M Bennett, J Thurman, M Radeva, D Gipson, F Kaskel, A Friedman, M M. Moxey-Mims, S Vento. Neutrophil Gelatinase-Associated Lipocalcin (NGAL) and Alternate Pathway of Complement (APC) Factors as Biomarkers of Response to Treatment in Patients with Focal Segmental Glomerulosclerosis (FSGS). Submitted to *ASN* 2011.
- Howard Trachtman, S Vento, D Gipson, S Wilcock, E Herreshoff, M Somers, L Gong, M Radeva, J McMahan, J Gassman, M Moxey-Mims. Novel Therapies In Resistant Fsgs (FONTt) Phase II Clinical Trial: Study Design And Updat. *Society for Clinical Trials*, Vancouver, 2011
- Howard Trachtman, Debbie S. Gipson, Frederick J. Kaskel, Tom H. Greene, Jennifer J. Gassman, Milena Radeva, Marva M. Moxey-Mims, Richard N. Fine, John Paul Middleton, V. Matti Vehaskari, Susan L. Hogan, Ronald J. Hogg, Sandra L. Watkins, Patricia Flynn, June McMahan, Leslie Powell, Suzanne M. Vento, Aaron L. Friedman. Results of the Multicenter FSGS Clinical Trial in Children and Young Adults. *American Society of Nephrology* November 20, 2010 in Denver, CO. Abstract 17541
- H Trachtman, R Fine, A Friedman, J Gassman, D Gipson, T Greene, R Hogg, FJ Kaskel, M Moxey-Mims, M Radeva, N Siegel*, and S Watkins. Quality of Life in Children with Focal Segmental Glomerulosclerosis (FSGS): Baseline Findings Report of the FSGS Clinical Trial (FSGS-CT). *J Am Soc Nephrol* 20:2009, 148A, TH-PO168.
- Trachtman H, Greene T, Gipson D. Novel Therapies for Resistant Focal Segmental Glomerulosclerosis (FSGS): A Phase I Study. CR 2006 Meetings, March 2006
- Joshua Truman, M Wong, M Radeva, D Gipson, F Kaskel, A Friedman, M Moxey-Mims, S Vento, H Trachtman. Activation of the Alternate Pathway of Complement (APC) in Focal Segmental Glomerulosclerosis (FSGS): Relationship to Proteinuria. *Pediatric Academic Societies Research Joint Meeting*, 2011